In-stent thrombosis after 68 months of implantation inspite of continuous dual antiplatelet therapy: a case report

Department of Medicine, Staten Island University Hospital, 475 Seaview Ave, Staten Island, NY-10305, USA. .
Cases Journal 02/2010; 3:68. DOI: 10.1186/1757-1626-3-68
Source: PubMed

ABSTRACT Lately, there has been an increased incidence of late stent thrombosis; especially following Drug eluting stent (DES) implantation. Several factors are associated with an increased risk of stent thrombosis, including the procedure itself, patient and lesion characteristics, stent design, and premature cessation of anti-platelet drugs. We present a case of late stent thrombosis (LST) following DES implantation after a period of 68 months, making it the longest reported case of LST reported in the literature, despite the use of dual anti-platelet therapy.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Drug eluting stents have been implanted worldwide and used in nearly 90% of percutaneous coronary interventions in China. Although many randomized trials have confirmed the efficacy and safety profile of drug eluting stents, they were not powered to detect or exclude the effect of drug eluting stents on rare events such as stent thrombosis. Several mechanisms of very late stent thrombosis have been postulated, but are not widely accepted. Virchow's triad describes the 3 main factors of thrombus formation - stasis of blood flow, endothelial injury and hypercoagulability. Myocardial bridging is a common congenital anomaly. Modern anatomy and angiography regard myocardial bridging as widespread, but its pathophysiological response is always ignored. According to Virchow's triad, myocardial bridging negatively affect endothelial function, and the turbulent shear stress and intimal trauma predispose the vessel toward thrombus formation. Therefore, we question whether a relationship between myocardial bridging and very late stent thrombosis of drug eluting stents exists. Also, we propose that myocardial bridging might be a potential risk factor of very late stent thrombosis of drug eluting stents; coronary artery bypass grafting might be a promising and novel choice in the treatment of myocardial bridging with severe stenosis in the coronary artery.
    Medical science monitor: international medical journal of experimental and clinical research 04/2012; 18(5):HY9-12. DOI:10.12659/MSM.882717 · 1.22 Impact Factor
  • International journal of cardiology 12/2011; 159(3):e53-5. DOI:10.1016/j.ijcard.2011.12.013 · 6.18 Impact Factor
  • Source
    Arquivos brasileiros de cardiologia 05/2013; 100(5):e59-e61. DOI:10.5935/abc.20130095 · 1.12 Impact Factor

Full-text (4 Sources)

Available from
Jun 4, 2014